{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:59:29Z","timestamp":1780714769218,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,8]]},"DOI":"10.7759\/cureus.55773","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T10:33:19Z","timestamp":1709893999000},"source":"Crossref","is-referenced-by-count":1,"title":["The Efficacy and Safety of Apremilast in the Management of Psoriatic Arthritis: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Renad F","family":"Alharthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joud M","family":"Alharthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan O","family":"Bawazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renad I","family":"Katib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fayez S","family":"Alharthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101692","article-title":"The epidemiology of psoriatic arthritis: a literature review","volume":"35","author":"Karmacharya P","year":"2021","unstructured":"Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: a literature review. Best Pract Res Clin Rheumatol. 2021, 35:101692. 10.1016\/j.berh.2021.101692","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref2","unstructured":"Psoriatic Arthritis. (2023). https.\/\/rheumatology.org\/patients\/psoriatic-arthritis."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315582354","article-title":"Psoriatic arthritis: latest treatments and their place in therapy","volume":"6","author":"Kang EJ","year":"2015","unstructured":"Kang EJ, Kavanaugh A. Psoriatic arthritis: latest treatments and their place in therapy. Ther Adv Chronic Dis. 2015, 6:194-203. 10.1177\/2040622315582354","journal-title":"Ther Adv Chronic Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14474","article-title":"Current treatment strategies and recommendations in psoriatic arthritis","volume":"26","author":"Kao PE","year":"2023","unstructured":"Kao PE, Lee YH, Ma KS, Ker A, Leung YY. Current treatment strategies and recommendations in psoriatic arthritis. Int J Rheum Dis. 2023, 26:8-10. 10.1111\/1756-185X.14474","journal-title":"Int J Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00861-w","article-title":"Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates LC","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al.. Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022, 18:734. 10.1038\/s41584-022-00861-w","journal-title":"Nat Rev Rheumatol"},{"key":"ref6","unstructured":"FDA Clears Apremilast (Otezla) for Psoriatic Arthritis. (2014). https.\/\/www.medscape.com\/viewarticle\/822396."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer PH","year":"2014","unstructured":"Schafer PH, Parton A, Capone L, et al.. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014, 26:2016-29. 10.1016\/j.cellsig.2014.05.014","journal-title":"Cell Signal"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170530093902","article-title":"Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives","volume":"24","author":"Sakkas LI","year":"2017","unstructured":"Sakkas LI, Mavropoulos A, Bogdanos DP. Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives. Curr Med Chem. 2017, 24:3054-67. 10.2174\/0929867324666170530093902","journal-title":"Curr Med Chem"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211568","article-title":"Early and sustained efficacy with apremilast monotherapy in biological-na\u00efve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)","volume":"77","author":"Nash P","year":"2018","unstructured":"Nash P, Ohson K, Walsh J, et al.. Early and sustained efficacy with apremilast monotherapy in biological-na\u00efve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis. 2018, 77:690-8. 10.1136\/annrheumdis-2017-211568","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh A","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al.. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014, 73:1020-6. 10.1136\/annrheumdis-2013-205056","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151376","article-title":"A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the Palace 2 Trial","volume":"43","author":"Cutolo M","year":"2016","unstructured":"Cutolo M, Myerson GE, Fleischmann RM, et al.. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the Palace 2 Trial. J Rheumatol. 2016, 43:1724-34. 10.3899\/jrheum.151376","journal-title":"J Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards CJ","year":"2016","unstructured":"Edwards CJ, Blanco FJ, Crowley J, et al.. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016, 75:1065-73. 10.1136\/annrheumdis-2015-207963","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/art.34627","article-title":"Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study","volume":"64","author":"Schett G","year":"2012","unstructured":"Schett G, Wollenhaupt J, Papp K, et al.. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012, 64:3156-67. 10.1002\/art.34627","journal-title":"Arthritis Rheum"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials","volume":"36","author":"Felson DT","year":"1993","unstructured":"Felson DT, Anderson JJ, Boers M, et al.. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993, 36:729-40. 10.1002\/art.1780360601","journal-title":"Arthritis Rheum"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries JF","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980, 23:137-45. 10.1002\/art.1780230202","journal-title":"Arthritis Rheum"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060079","article-title":"Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate","volume":"66","author":"Gratac\u00f3s J","year":"2007","unstructured":"Gratac\u00f3s J, Casado E, Real J, Torre-Alonso JC. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis. 2007, 66:493-7. 10.1136\/ard.2006.060079","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/ar2848","article-title":"ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature","volume":"11","author":"Alivernini S","year":"2009","unstructured":"Alivernini S, Laria A, Gremese E, Zoli A, Ferraccioli G. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Res Ther. 2009, 11:R163. 10.1186\/ar2848","journal-title":"Arthritis Res Ther"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"The PRISMA 2020 Statement. An Updated Guideline for Reporting Systematic Reviews\r\n. (2021). Accessed: December 15, 2023: https:\/\/www.bmj.com\/content\/372\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2016.10.005","article-title":"Effectiveness of conventional disease-modifying antirheumatic drugs in psoriatic arthritis: a systematic review","volume":"14","author":"Maese J","year":"2018","unstructured":"Maese J, D\u00edaz Del Campo P, Seoane-Mato D, Guerra M, Ca\u00f1ete JD. Effectiveness of conventional disease-modifying antirheumatic drugs in psoriatic arthritis: a systematic review. Reumatol Clin (Engl Ed). 2018, 14:81-9. 10.1016\/j.reuma.2016.10.005","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15482","article-title":"Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation","volume":"33","author":"Dressler C","year":"2019","unstructured":"Dressler C, Eisert L, Pham PA, Nast A. Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation. J Eur Acad Dermatol Venereol. 2019, 33:1249-60. 10.1111\/jdv.15482","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0787-7","article-title":"The effectiveness of a traditional therapeutical approach in early psoriatic arthritis:\r\nresults of a pilot randomised 6-month trial with methotrexate","volume":"27","author":"Scarpa R","year":"2018","unstructured":"Scarpa R, Peluso R, Atteno M, et al.. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis:\r\nresults of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol. 2018, 27:823-6. 10.1007\/s10067-007-0787-7","journal-title":"Clin Rheumatol"},{"key":"ref23","article-title":"Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a\r\nlongitudinal observational cohort","volume":"35","author":"Chandran V","year":"2008","unstructured":"Chandran V, Schentag CT, Gladman DD, et al.. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a\r\nlongitudinal observational cohort. J Rheumatol. 2008, 35:469-71.","journal-title":"J Rheumatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis","volume":"6","author":"Ruyssen-Witrand A","year":"2020","unstructured":"Ruyssen-Witrand A, Perry R, Watkins C, et al.. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020, 6:e001117. 10.1136\/rmdopen-2019-001117","journal-title":"RMD Open"},{"key":"ref25","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"7","author":"Gossec L","year":"2015","unstructured":"Gossec L, Smolen JS, Ramiro S, et al.. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. ARD. 2015, 7:499-510.","journal-title":"ARD"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2016.1159130","article-title":"A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE)","volume":"9","author":"Qu X","year":"2016","unstructured":"Qu X, Zhang S, Tao L, Song Y. A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE). Expert Rev Clin Pharmacol. 2016, 9:799-805. 10.1586\/17512433.2016.1159130","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3919-7","article-title":"Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis","volume":"38","author":"Kawalec P","year":"2018","unstructured":"Kawalec P, Holko P, Mo\u0107ko P, Pilc A. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatol Int. 2018, 38:189-201. 10.1007\/s00296-017-3919-7","journal-title":"Rheumatol Int"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2016.1140026","article-title":"An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-na\u00efve patients with psoriatic arthritis","volume":"32","author":"Betts KA","year":"2016","unstructured":"Betts KA, Griffith J, Friedman A, Zhou ZY, Signorovitch JE, Ganguli A. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-na\u00efve patients with psoriatic arthritis. Curr Med Res Opin. 2016, 32:721-9. 10.1185\/03007995.2016.1140026","journal-title":"Curr Med Res Opin"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/234478-the-efficacy-and-safety-of-apremilast-in-the-management-of-psoriatic-arthritis-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T10:33:25Z","timestamp":1709894005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/234478-the-efficacy-and-safety-of-apremilast-in-the-management-of-psoriatic-arthritis-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.55773","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,8]]}}}